ArticleiGIE : innovation, investigation and insights2026
The role of quantitative contrast-enhanced endoscopic ultrasound in the differential diagnosis of pancreatic solid neoplasms: a proof-of-concept prospective study shifting from subjective to objective.
Article in iGIE : innovation, investigation and insights, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Accurate differentiation of pancreatic solid tumors, including pancreatic neuroendocrine neoplasms (pNENs) and pancreatic ductal adenocarcinomas (PDACs), is crucial because of their distinct prognoses and treatments. Contrast-enhanced endoscopic ultrasound (CE-EUS) assesses vascularization differences but is limited by subjective interpretation and low interobserver agreement. The aim of this article is to evaluate the role of quantitative CE-EUS in differentiating pNENs from PDACs. Methods: This observational study included patients with a cytological diagnosis of PDACs or pNENs undergoing CE-EUS from January to June 2024. CE-EUS videos were analyzed using software for objective contrast quantification. Vascular parameters were compared between tumor types using Mann-Whitney Results: Among 73 patients (51 with PDACs/22 with pNENs), pNENs had significantly greater contrast intensity, peak enhancement, and wash-in area under the curve. Receiver operating characteristic curves identified wash-in perfusion index and wash-in rate as the most discriminative parameters, achieving an area under the curve of 96.1% when combined. Conclusions: Quantitative CE-EUS appears to enhance pancreatic tumor differentiation by eliminating subjectivity and improving diagnostic accuracy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.